Immunome, Inc. (NASDAQ:IMNM - Free Report) - Stock analysts at Leerink Partnrs upped their Q1 2024 EPS estimates for shares of Immunome in a research note issued on Tuesday, March 26th. Leerink Partnrs analyst A. Berens now expects that the company will earn ($1.71) per share for the quarter, up from their previous forecast of ($2.21). Leerink Partnrs has a "Outperform" rating on the stock. The consensus estimate for Immunome's current full-year earnings is ($0.97) per share. Leerink Partnrs also issued estimates for Immunome's Q2 2024 earnings at ($0.15) EPS, Q3 2024 earnings at ($0.18) EPS, Q4 2024 earnings at ($0.22) EPS, FY2024 earnings at ($2.17) EPS, FY2025 earnings at ($2.29) EPS and FY2026 earnings at ($2.90) EPS.
A number of other research firms also recently issued reports on IMNM. SVB Leerink assumed coverage on shares of Immunome in a research report on Monday, January 29th. They set an "outperform" rating and a $30.00 target price on the stock. Wedbush upped their target price on shares of Immunome from $12.00 to $19.00 and gave the company an "outperform" rating in a research report on Tuesday, January 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has an average rating of "Buy" and an average price target of $24.50.
Get Our Latest Analysis on Immunome
Immunome Trading Down 3.3 %
NASDAQ IMNM traded down $0.84 on Friday, hitting $24.68. 1,258,056 shares of the company were exchanged, compared to its average volume of 589,994. The firm has a 50 day moving average of $22.54 and a two-hundred day moving average of $13.59. The company has a market cap of $1.35 billion, a P/E ratio of -13.64 and a beta of 1.67. Immunome has a 1-year low of $4.44 and a 1-year high of $30.96.
Institutional Trading of Immunome
A number of institutional investors and hedge funds have recently modified their holdings of IMNM. Renaissance Technologies LLC bought a new stake in shares of Immunome in the 1st quarter valued at about $80,000. First Republic Investment Management Inc. bought a new stake in shares of Immunome in the 1st quarter valued at about $87,000. UBS Group AG increased its stake in shares of Immunome by 1,049.9% in the 3rd quarter. UBS Group AG now owns 15,271 shares of the company's stock valued at $68,000 after acquiring an additional 13,943 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Immunome by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 373,685 shares of the company's stock valued at $1,659,000 after acquiring an additional 3,149 shares during the last quarter. Finally, Natixis bought a new stake in shares of Immunome in the 4th quarter valued at about $25,000. 44.58% of the stock is owned by institutional investors.
Immunome Company Profile
(
Get Free Report)
Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.
Further Reading
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
